Melatonina u ssaków - związek o wielu funkcjach

• Authors: Ewa Chwełatiuk

Title variants

EN

Melatonin in mammals - a multipurpose compound

• Languages of publication: PL EN

Abstracts

EN

Melatonin is an indoloamine of widespread distribution in the plant and animal kingdoms. N-acetyl-5-methoxytryptamine is regarded as a hormone as well as paracoid and autocoid. In mammals, melatonin is mainly synthesized by the pineal gland and its biosynthesis exhibits a circadian rhythm which depends on the light conditions and is controlled by the endogenous biological clock (SCN). This compound exerts a number of receptor mediated actions including chronobiotic effects and very likely has a property to increase the activity of antioxidative enzymes. Melatonin also is able to reduce the oxidative stress in a receptor independent way through free radicals' scavenging. People commonly use melatonin as a drug reducing jet lag, insomnia and in the supportive therapy of cancer.

• Journal: Kosmos
• Year: 2008
• Volume: 57
• Issue: 1-2
• Pages: 93-102

Dates

published

2008

Contributors

author

Ewa Chwełatiuk

• Uniwersytet w Białymstoku, Instytut Biologii, Świerkowa 20B 15-950 Białystok, Polska

References

• Alarma-Estrany P., Pintor J., 2007. Melatonin receptors in the eye, location, second messengers and role in ocular physiology. Pharmacol. Ther. 113, 507-522.
• Allegra M., Reiter R. J., Tan D.-X., Gentile C., Tesoriere L., Livrea M. A., 2003. The chemistry of melatonin's interaction with reactive species. J. Pineal Res. 34, 1-10.
• Anisimov V. N., Popovich I. G., Zabezhinski M. A., Anisimov S. V., Vesnushkin G. M., Vinogradova I. A., 2006. Melatonin as antioxidant, geroprotector and anticarcinogen. Biochim. Biophys. Acta 1757, 573-589.
• Antunes F., Barclay R. C., Ingold K. U., King M., Norris J. Q., Scalano J. C., Xi F., 1999. On the antioxidant activity of melatonin. Free Radic. Biol. Med. 26, 117-128.
• Armstrong S. M., 1989. Melatonin, the internal zeitgeber of mammals? Pineal Res. Rev. 7, 157-202.
• Barrett P., Conway S., Morgan P. J., 2003. Digging deep - structure - function relationships in the melatonin receptor family. J. Pineal Res. 35, 221-230.
• Bartness T. J., Demas G. E., Song C. K., 2002. Seasonal changes in adiposity, the roles of the photoperiod, melatonin and other hormones, and sympathetic nervous system. Exp. Biol. Med. 6, 363-376.
• Cardinali D. P., Pévet P., 1998. Basic aspects of melatonin action. Sleep Med. Rev. 2, 175-190.
• Cardinali D. P., Golombek D. A., Rosenstein R. E., Cutrera R. A., Esquifino A. I., 1997. Melatonin site and mechanism of action, single or multiple? J. Pineal Res. 23, 32-39.
• Claustrat B., Brun J., Chazot G., 2005. The basic physiology and pathophysiology of melatonin. Sleep Med. Rev. 9, 11-24.
• Derewecka-Dzięgiel E., Dzięgiel P., 1997. Melatonina - fakty, hipotezy, perspektywy terapeutyczne. Post. Med. Klin. Dośw. 6, 387-394.
• Dubocovich M. L., Cardinali D. P., Guardiola-Lemaitre B., Hagan R. M., Krause D. N., Sugden B., Vanhoutte P. M., Yocca F. D., 1998. Melatonin receptors. The IUPHAR compendium of receptor characterisation and classification. IUPHAR Media, London, 187-193.
• Dubocovich M. L., Rivera-Bermundez M. A., Gerdin M. J., Masana M. J., 2003. Molecular pharmacology, regulation and function of melatonin receptors. Front. Biosci. 8, d1093-d1108.
• Dzięgiel P., Jethon Z., Markiewicz-Górska I., Januszewska L., 1997. Antioxidative role of melatonin in lead-induced intoxication. Pol. J. Environ. Stud. 6 (Suppl.), 40-42.
• Ekmekcioglu C., 2006. Melatonin receptors in humans, biological role and clinical relevance. Biomed. Pharmacother. 60, 97-108.
• Erkoç Ş., Erkoç F., Keskin N., 2002. Theoretical investigation of melatonin and its hydroxy isomers. J. Mol. Str. 587, 73-79.
• Gozzo A., Lesieur D., Duriez P., Fruchart J. Ch., Teissier E., 1999. Structure-activity relationships in a series of melatonin analogues with the low-density lipoprotein oxidation model. Free Radic. Biol. Med. 26, 1538-1543.
• Guerrero J. M., Pozo D., Garcia-Mauriño S., Osuna C., Molinero P., Calvo J. R., 2000. Involvement of nuclear receptors in the enhanced IL-2 production by melatonin in jurkat cells. Ann N.Y. Acad. Sci. 917, 397-403.
• Gulcin I., Buyukokuroglu M. E., Oktay M., Kufrevioglu O. I., 2002. On the in vitro antioxidative properties of melatonin. J. Pineal Res. 33, 167-171.
• Gulcin I., Buyukokuroglu M. E., Kufrevioglu O. I., 2003. Metal chelating and hydrogen peroxide scavenging effects of melatonin. J. Pineal Res. 34, 278-281.
• Hardeland R., 2005. Antioxidative protection by melatonin. Endocrine 27, 119-130.
• Hardeland R., Poeggeler B., 2003. Non-vertebrate melatonin. J. Pineal Res. 34, 233-241.
• Hardeland R., Coto-Montes A., Poeggeler B., 2003. Circadian rhythms, oxidative stress, and antioxidative defenses mechanisms. Chronobiol. Int. 20, 921-926.
• Hardeland R., Pandi-Perumal S. R., Cardinali D. P., 2006. Melatonin. Int. J. Biochem. Cell Biol. 38, 313-316.
• Karasek M., 1997. Szyszynka i melatonina. Wydawnictwo Naukowe PWN, Warszawa-Łódź.
• Karbownik M., Gitto E., Lewinski A., Reiter R. J., 2001a. Induction of lipid peroxidation in hamster organs by the carcinogen cadmium, amelioration by melatonin. Cell Biol. Toxicol. 17, 33-40.
• Karbownik M., Lewinski A., Reiter R. J., 2001b. Anticarcinogenic actions of melatonin which involve antioxidative processes, comparison with other antioxidants. Int. J. Biochem. Cell Biol. 33, 735-753.
• Kulikowska-Karpińska E., Moniuszko-Jakoniuk J., 2004. The antioxidative barrier in the organism. Pol J. Environ. Stud. 13, 5-13.
• Lahiri D., Ge Y.-W., Sharman E. H., Bondy S. C., 2004. Age-related changes in serum melatonin in mice, higher levels of combined melatonin and 6-hydroxymelatonin sulfate in the cerebral cortex than serum, heart, liver and kidney tissues. J. Pineal Res. 36, 217-223.
• Lathrop N. J., Lentz M., 2001. Melatonin, light therapy, and jet lag. Air Med. J. 20, 30-34.
• Lenoir V., de Jonage-Canonico M. B. Y., Perrin M.-H., Martin A., Scholler R., Kerdehué B., 2005. Preventive and curative effect of melatonin on mammary carcinogenesis induced by dimethylbenz[a]anthracene in the female Sprague-Dawley rat. Breast Cancer Res. 7, R470-R476.
• Leon J., Acuna-Castroviejo D., Sainz R.M., Mayo J. C., Tan D.-X., Reiter R. J., 2004. Melatonin and mitochondrial function. Life Sci. 75, 765-790.
• Leon J., Acuna-Castroviejo D., Escames G., Tan D.-X., Reiter R. J., 2005. Melatonin mitigates mitochondrial malfunction. J. Pineal Res. 38, 1-9.
• Lerner A. B., Case J. D., Takahashi Y., 1958. Isolation of melatonin, a pineal factor that lightens melanocytes. J. Am. Chem. Soc. 80, 2057-2058.
• Lewy A. J., Ahmed S., Sack R. L., 1996. Phase shifting the human circadian clock using melatonin. Behav. Brain Res. 73, 131-134.
• Livrea M. A., Tesoriere L., D'Arpa D., Morreale M., 1997. Reaction of melatonin with lipoperoxyl radicals in phospholipid bilayers. Free Radic. Biol. Med. 23, 706-711.
• Maksimovich A. A., 2002. Structure and function of the vertebrate pineal gland. J. Evol. Biochem. Physiol. 38, 1-15.
• Manchester L. C., Poeggeler B., Alvares F. L., Ogden G. B., Reiter R. J., 1995. Melatonin immunoreactivity in the photosynthetic procaryote Rhodospirillum rubrum, implications for an ancient antioxidant system. Cell. Mol. Biol. Res. 41, 391-395.
• Marnett L. J., 2000. Oxyradicals and DNA damage. Carcinogenesis 21, 361-370.
• Marshall K.-A., Reiter R. J., Poeggeler B., Aruoma O. I., Halliwell B., 1996. Evaluation of the antioxidant activity of melatonin in vitro. Free Radic. Biol. Med. 21, 307-315.
• Mayo J. C., Sainz R. M., Antolin I., Herrera F., Martin V., Rodriguez C., 2002. Melatonin regulation of antioxidant enzyme gene expresion. Cell. Mol. Life Sci. 59, 1706-1713.
• Mayo J. C., Sainz R. M., Tan D.-X., Hardeland R., Leon J., Rodriguez C., Reiter R. J., 2005. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J. Neuroim. 165, 139-149.
• McGeer P. L., McGeer E. G., 2001. Inflammation, autotoxicity and Alzheimer disease. Neurobiol. Aging 22, 799-809.
• Moller M., Baeres F. M. M., 2002. The anatomy and innervation of the mammalian pineal gland. Cell Tissue Res. 309, 139-150.
• Nelson R. J., Drazen D. L., 1999. Melatonin mediates seasonal adjustments in immune function. Reprod. Nutr. Dev. 39, 383-398.
• Niedziela M., Lerchl A., Nieschlag E., 1995. Direct effects of the pineal hormone melatonin on testosterone synthesis of Leydig cells in Djungarian hamsters (Phodopus sungorus) in vitro. Neurosci. Lett. 201, 247-250.
• Nowak J. Z., Zawilska J. B., 1998. Melatonin and its physiological and therapeutic properties. Pharm. World Sci. 20, 18-27.
• Ostrowski K. (red.), 1995. Histologia. Wydawnictwo Lekarskie PZWL, Warszawa.
• Pévet P., Bothorel B., Slotten H., Saboureau M., 2002. The chronobiotic properties of melatonin. Cell Tissue Res. 309, 183-191.
• Pieri C., Moroni F., Marra M., Marcheselli F., Recchioni R., 1995. Melatonin is an efficient antioxidant. Arch. Gerontol. Geriatr. 20, 159-165.
• Pintor J., Pelaez T., Hoyle C. H., Peral A., 2003. Ocular hypotensive effects of melatonin receptor agonists in the rabbit: further evidence for an MT3 receptor. Br. J. Pharmacol. 138, 831-836.
• Rao G. N., Ney E., Herbert R. A., 2000. Effect of melatonin and linolenic acid on mammary cancer in transgenic mice with c-neu breast cancer oncogene. Breast Cancer Res. Treat. 64, 287-296.
• Reiter R. J., 1998. Cytoprotective properties of melatonin, presumed association with oxidative damage and aging. Nutrition 14, 691-696.
• Reiter R. J., 2003. Melatonin, clinical relevance. Best Pract. Res. Clin. Endocrinol. Metab. 17, 273-285.
• Reiter R., Tang L., Garcia J. J., Muñoz-Hoyos A., 1997. Pharmacological actions of melatonin in oxigen radical pathophysiology. Life Sci. 60, 2255-2271.
• Reiter R. J., Tan D.-X., Mayo J. C., Lopez-Burillo S., 2002. Melatonin, reducing the toxicity and increasing the efficacy of drugs. J. Pharm. Pharmacol. 54, 1299-1321.
• Reiter R. J., Tan D.-X., Terron M. P., Flores L. J., Czarnocki Z., 2007. Melatonin and its metabolites: new findings regarding their production and their scavenging actions. Acta Biochim. Polon. 54, 1-9.
• Rodriguez C., Mayo J. C., Sainz R. M., Antolín I, Herrera F., Martín V., Reiter R. J., 2004. Regulation of antioxidant enzymes, a significant role for melatonin. J. Pineal. Res. 36, 1-9.
• Sainz R. M., Mayo J. C., Rodriguez C., Tan D. X., Lopez-Burillo S., Reiter R. J., 2003. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell. Mol. Life Sci. 60, 1407-1426.
• Scheer F. A. J. L., Czeisler Ch. A., 2005. Melatonin, sleep, and circadian rhythms. Sleep Med. Rev. 9, 5-9.
• Stadtman E. R., 1992. Protein oxidation and aging. Science 257, 1220-1224.
• Steinhilber D., Brungs M., Werz O., Wiesenberg I, Danielsson C., Kahlen j. P., Nayeri S., Schräder M., Carlberg C., 1995. The nuclear receptor for melatonin repress 5-lipooxygenase gene expression in human B lymphocytes. J. Biol. Chem. 270, 7037-7040.
• Tan D.-X., Chen L. D., Poeggeler B., Menchester L. C., Reiter R. J., 1993. Melatonin, a potent endogenous hydroxyl radical scavenger. Endocr. J. 1, 57-60.
• Tan D.-X., Manchester L. C., Reiter R. J., Plummer B. F., Hardies L. J., Weintraub S. T., Vijayalaxmi, Shepherd A. M. M., 1998. A novel melatonin metabolite, cyclic 3-hydroxymelatonin, a biomarker of in vivo hydroxyl radical generation. Biochem. Biophys. Res. Commun. 253, 614-620.
• Tan D.-X., Manchester L. C., Reiter R. J., Qi W., Zhang M., Weintraub S. T., Cabrera J., Sainz R. M., Mayo J. C., 1999. Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochim. Biophys. Acta 1472, 206-214.
• Tan D.-X., Manchester L. C., Reiter R. J., Plummer B. F., Limson J., Weintraub S. T., Qi W., 2000. Melatonin directly scavenges hydrogen peroxide, a potentially new metabolic pathway of melatonin biotransformation. Free Radic. Biol. Med. 29, 1177-1185.
• Tan D.-X., Manchester L. C., Hardeland R., Lopez-Burillo S., Mayo J., Sainz R. M., Reiter R. J., 2003. Melatonin, a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J. Pineal Res. 34, 75-78.
• Teclemariam-Mesbah R., Ter Horst G. J., Postema F., Wortel J., Bujis R. M., 1999. Anatomical demonstration of the suprachiasmatic nucleus-pineal pathway. J Comp. Neurol. 406, 171-182.
• Tricoire H., Locatelli A., Chemineau P., Malpaux B., 2002. Melatonin enters the cerebrospinal fluid through the pineal recess. Endocrinology 143, 84-90.
• van Tassel D. L., Roberts N., Lewy A., O'Neil S. D., 2001. Melatonin in plant organs. J. Pineal Res. 31, 8-15.
• von Gall Ch., Stehle J. H., Weaver D. R., 2002. Mammalian melatonin receptors, molecular biology and signal transduction. Cell Tissue Res. 309, 151-162.
• Witt-Enderby P. A., Bennett J., Jarzynka M. J., Firestine S., Melan M. A., 2003. Melatonin receptors and their regulation, biochemical and structural mechanisms. Life Sci. 72, 2183-2198.
• Zatta P., Tognon G., Carampin P., 2003. Melatonin prevents free radical formation due to the interaction between β-amyloid peptides and metal ions [Al (III), Zn (II), Cu (II), Mn (II), Fe (II)]. J. Pineal Res. 35, 98-103.
• Zeitzer J. M., Dijk D., Kronauer R. E., Brown E. N., Czeisler C. A., 2000. Sensitivity of the human circadian pacemaker to nocturnal light: melatonin phase resetting and suppression. J. Physiol. 526, 695-702.